Fig 1.
Study subject disposition.
Table 1.
Demographic and baseline clinical features of study subjects.
Table 2.
Baseline haematological and biochemical values of study subject.
Fig 2.
Increase in the mean (± s.e.m) platelet counts during course of treatment in the treatment group (black) and Placebo group (grey) subjects.
Fig 3.
Mean (± s.e.m) percent increase in platelet count post treatment (day 3) in treatment group (black) and placebo group (grey) subjects.
Fig 4.
Mean (± s.e.m) percentage increase in platelet count post treatment (day 3) in treatment group (black) and placebo group (grey) subjects in the febrile, critical and recovery phases of dengue illness.
Fig 5.
Mean (± s.e.m) percentage increase in platelet count post treatment (day 3) in treatment group (black) and placebo group (grey) subjects with primary and secondary dengue infection.
Fig 6.
Mean (± s.e.m) percentage increase in platelet count post treatment (day 3) in treatment group (black) and placebo group (grey) in the NS1 (+) and NS (-) subgroup of study subjects.
Fig 7.
Kaplan-Meier estimates of probability of platelet count of ≤ 50000 per μL by day 6 in treatment group (black) and placebo group (grey).
HR denotes hazard ratio.
Fig 8.
Increase in the mean (± s.e.m) hematocrit values during course of treatment in the treatment group (black) and placebo group (grey) subjects.
Fig 9.
Mean (± s.e.m) percent decrease in HCT value (%) post treatment (day 3) in treatment group (black) and placebo group (grey) subjects.
Table 3.
Days of hospitalization of patients in treatment and placebo group.
Table 4.
Platelet transfusion details of study subjects in treatment and placebo groups.
Fig 10.
Mean percentage (±s.e.m) changes in plasma cytokine levels by 72 hrs (day 3) in the treatment group (black) and placebo group (grey) (a) IFN-γ (b) TNF-α (c) IL-6 (d) IL-4.
Table 5.
Mean (±se.m) plasma levels of cytokines measured on day 0 (pre-treatment) and day 3 (post-treatment) in study subjects (n = 20).
Fig 11.
Mean (± s.e.m) percentage decrease in plasma viral NS1 titers by day 3 in treatment group (black) and placebo group (grey) subjects.